ELRIG-Forum 2014: Abstracts
Dr. Jochen Beninga, Sanofi, Frankfurt, Germany
SAR156597, an engineered bispecific antibody, simultaneously binds both IL-4 and IL-13 with high affinity and may attenuate the pathogenesis of idiopathic pulmonary fibrosis, a severe disease with few therapeutic options and a mean survival time of 3 years. This talk will describe the generation of SAR156597 as case study for multispecific biotherapeutics an area that has seen tremendous advances in the last years.
David Booth, Titian Software Ltd, London, UK
As high throughput technology is implemented across laboratories and research facilities on an ever-increasing scale, the generation of new biological entities (NBEs) continues to rise. In addition the explosion in the growth of ‘Biobanks’ presents ever more diverse samples requiring management - ranging from proteins, DNA and tissue, to agronomic seed banks and biodiversity species collections (alive and extinct).
